Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arctic Bioscience AS ( (DE:9TD) ) has provided an update.
Arctic Bioscience has announced the results of its phase 2b HeROPA study, which evaluated the efficacy and safety of its drug candidate HRO350 for treating mild to moderate psoriasis. While the primary endpoint was not met due to a high placebo response, secondary endpoints showed promising results, and the drug was well tolerated with no serious side effects. The company sees significant market potential for HRO350 and plans to pursue partnerships for further development, while also seeking to understand the high placebo response to improve future studies.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company specializing in the development and commercialization of pharmaceutical products and dietary supplements derived from unique bioactive marine raw materials. The company is currently developing HRO350, an oral drug candidate aimed at treating mild to moderate psoriasis, a condition affecting a large patient population in need of effective and safe treatments. Their dietary supplements are marketed globally under the brand ROMEGA®.
Average Trading Volume: 53,050
Current Market Cap: NOK87.56M
Find detailed analytics on 9TD stock on TipRanks’ Stock Analysis page.